Ionis Pharmaceuticals, Inc. Common Stock (IONS) Financials
Key financial figures for Ionis Pharmaceuticals, Inc. Common Stock (Q2 2026).
Ionis Pharmaceuticals, Inc. reported revenue of $267.9 million for Q2 FY2026, down 40.7% from the same period a year earlier. The company posted a net loss of $114.6 million, or -$0.69 per share. Operating margin came to -38.18%, against 30.93% a year earlier. Free cash flow for the period was $549.5 million. Across the last 5 reported quarters, quarterly revenue has moved from $452.0 million in Q2 FY2025 to $267.9 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Ionis Pharmaceuticals, Inc. are on the SentiSense financials page.
- Revenue
- $268M
- Net Income
- -$115M
- EPS
- $-0.69
- Total Assets
- $3.0B
- Operating Cash Flow
- $566M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $268M | -$115M | -$0.69 | -38.18% | $549M |
| Q1 FY2026 | $246M | -$93M | -$0.56 | -47.72% | -$815M |
| Q4 FY2025 | $203M | -$229M | -$1.41 | -105.91% | -$159M |
| Q3 FY2025 | $157M | -$129M | -$0.80 | -102.21% | -$135M |
| Q2 FY2025 | $452M | $124M | $0.68 | 30.93% | $137M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $944M | -$381M | -$2.38 | -40.47% | -$320M |
| FY2024 | $705M | -$454M | -$3.04 | -67.37% | -$546M |
| FY2023 | $788M | -$366M | -$2.56 | -44.91% | -$336M |
Frequently asked questions
What was Ionis Pharmaceuticals, Inc.'s revenue last quarter?
Ionis Pharmaceuticals, Inc. reported revenue of $267.9 million for Q2 FY2026, down 40.7% from the same period a year earlier.
Is Ionis Pharmaceuticals, Inc. profitable?
Not in its most recent reported period. Ionis Pharmaceuticals, Inc. reported a net loss of $114.6 million for Q2 FY2026, a net margin of -42.79% on revenue.
How has Ionis Pharmaceuticals, Inc.'s margin trended?
Operating margin was -38.18% in Q2 FY2026, compared with 30.93% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Ionis Pharmaceuticals, Inc. generate?
Ionis Pharmaceuticals, Inc. generated free cash flow of $549.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Ionis Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.